Jones KL, et al. – In this study involving 15 healthy control participants and 15 participants with type 2 diabetes (T2DM), researchers assessed the impact of lixisenatide on gastric emptying, blood pressure (BP), and superior mesenteric artery (SMA) blood flow, as well as the glycemic responses to a 75-g oral glucose load. Study participants had measurements of gastric emptying, BP, SMA flow, and plasma glucose recorded 180 minutes following a radiolabeled 75-g glucose drink on two separate days. All participants received lixisenatide (10 μg subcutaneously) or placebo 30 minutes before the glucose drink in a randomized, double-blind, crossover fashion. Investigators found that the significant slowing of gastric emptying of lixisenatide-induced glucose was related to the attenuation of the increments in glycemia and SMA flow and reduction in systolic BP—both in control participants and those with T2DM. Lixisenatide might, therefore, be useful in postprandial hypotension management.